Virology News and Research

Latest Virology News and Research

Study suggests causal link between HSV1 and Alzheimer's disease

Laboratories at the University of New Mexico (UNM), Brown University, and House Ear Institute (HEI) have developed a new technique to observe herpes simplex virus type 1 (HSV1) infections growing inside cells. HSV1, the cause of the common cold sore, persists in a latent form inside nerve cells.

5 Apr 2011

Boehringer Ingelheim receives FDA approval for Viramune XR to treat HIV-1 infection

Boehringer Ingelheim Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration has approved Viramune XR extended-release tablets, a one-pill, once-daily formulation of nevirapine for use in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults.

5 Apr 2011

Optimer study highlights economic burden of acute and recurrent CDI in hospital patients

Optimer Pharmaceuticals, Inc. announced today the presentation of information from insurance claims and survey databases highlighting the unmet need for targeted therapies to treat subpopulations at high risk of recurrence of Clostridium difficile infection.

4 Apr 2011

Oral cancer more common among Americans with HPV16 viral infections

A serious change in the cause of oral cancer is taking place nationally, and its implications are impacting the American public in a manner that a decade ago no one would have predicted.

4 Apr 2011

Study demonstrates in vitro infection and HEV replication in human hepatocytes

Groundbreaking data presented today demonstrates, for the first time, in vitro infection and replication of swine hepatitis E virus in human hepatocytes.

4 Apr 2011

Entry inhibitors can provide first new hepatitis B & D treatments for many years

Promising new viral hepatitis data presented today at the International Liver CongressTM show that entry inhibitors --a new mechanism of action for drugs to treat viral hepatitis -- could provide the first new hepatitis B and hepatitis D treatments for many years.

2 Apr 2011

Experts must monitor new antiviral compounds for HCV treatment

Data presented at the International Liver CongressTM highlight the fact that new novel antiviral compounds for the treatment of hepatitis C virus must be prescribed and monitored by experts and specialists to ensure resistance is minimised.

2 Apr 2011

Idera's IMO-2125 plus ribavirin Phase 1 trial results against HCV presented at EASL meeting

Idera Pharmaceuticals, Inc. announced today the presentation of data from a four-week Phase 1 clinical trial of IMO-2125 in combination with ribavirin in treatment-naïve patients chronically infected with hepatitis C virus genotype 1.

2 Apr 2011

MSD's Victrelis Phase III trial final results against HCV presented at EASL meeting

MSD reported that final results from a Phase III study of 'Victrelis', its investigational oral hepatitis C protease inhibitor, added to peginterferon alfa-2a marketed by Roche Products Limited, and ribavirin therapy were presented for the first time today as part of a late-breaker poster session at The International Liver Congress / 46th European Association for the Study of the Liver annual meeting.

2 Apr 2011

Boehringer Ingelheim's BI 201335 new data against HCV highlighted at EASL meeting

New data presented today at the International Liver CongressTM 2011, the 46th Annual Meeting of the European Association for the Study of the Liver, in Berlin, highlighted the efficacy of Boehringer Ingelheim's once-daily oral protease inhibitor BI 201335, in both treatment-naïve and -experienced patients with chronic genotype-1 hepatitis C virus infection. Genotype-1 HCV is the most challenging genotype of HCV to treat.

2 Apr 2011

Boehringer Ingelheim advances into Phase 3 clinical trial of BI 201335

Boehringer Ingelheim today announced a preview of the study designs for the pivotal Phase 3 clinical trials evaluating BI 201335, its investigational once-daily oral protease inhibitor, in both treatment-naive and -experienced patients with chronic genotype-1 hepatitis C virus, the most challenging genotype to treat.

2 Apr 2011

Series of new clinical trials confirm range of viable treatment options for HCV patients

Highly anticipated data from a number of clinical trials presented for the first time at the International Liver CongressTM confirmed that a range of new proteases inhibitors will help treat patients who have previously failed therapy for the treatment of chronic hepatitis C.

2 Apr 2011

Oral Cancer Awareness Week aims to educate people regarding importance of early detection

The 2011 Oral Cancer Awareness Week, set for April 11-15, is intended to educate people of all ages and socio-economic levels about the risk factors and symptoms of oral, head and neck cancer and the importance of early detection.

2 Apr 2011

Results of Boehringer Ingelheim's BI 201335 study presented at Annual Meeting of EASL

New data presented today at the 46th Annual Meeting of the European Association for the Study of the Liver demonstrate the antiviral activity of Boehringer Ingelheim's once-daily oral protease inhibitor, BI 201335, in both treatment-naive and -experienced patients with chronic genotype-1 hepatitis C virus, the most challenging genotype of HCV to treat.

1 Apr 2011

Microbix closes private financing for $0.35 per share

Microbix Biosystems Inc., a biotechnology company focused on virology and biological technologies, today announced the closing of the first tranche of a private placement resulting in the issue of 400,000 Units at a price of $0.35 per Unit.

1 Apr 2011

Invida, Roche partner to commercialize primary care products

Invida Group Pte Ltd, the leading specialty pharmaceutical company focused on the commercialization of healthcare products throughout Asia Pacific, today announced that it has entered into a partnership agreement with Roche for the commercialization and marketing of that company's primary care portfolio throughout Korea.

1 Apr 2011

Lymphocyte-hepatocyte interactions: Hepatitis C virus changes the rules

New data presented at the International Liver CongressTM today show the existence of novel interactions between T cells and hepatocytes that are regulated by HCV infection, providing a novel understanding of how HCV persists in the liver.

1 Apr 2011

Potential HIV vaccine component undergoes dramatic protein rearrangement

An international study headed by a UC Davis scientist describes how a component of a potential HIV vaccine opens like a flower, undergoing one of the most dramatic protein rearrangements yet observed in nature. The finding could reveal new targets for vaccines to prevent HIV infection and AIDS. A paper describing the work was published online this week in the journal Proceedings of the National Academy of Sciences.

1 Apr 2011

Scientists engineer new protein that prevents HIV virus entry into cells

In what could be a potential breakthrough in the battle against AIDS and a major development in the rational design of new drugs, scientists have engineered a new protein that prevents the virus from entering cells.

1 Apr 2011

New research finds HIV virus's V3 loop as attractive vaccine target

A section of the AIDS virus's protein envelope once considered an improbable target for a vaccine now appears to be one of the most promising, new research by Dana-Farber Cancer Institute scientists indicates.

1 Apr 2011

Virology News and Research

Latest Virology News and Research

Study suggests causal link between HSV1 and Alzheimer's disease

Boehringer Ingelheim receives FDA approval for Viramune XR to treat HIV-1 infection

Optimer study highlights economic burden of acute and recurrent CDI in hospital patients

Oral cancer more common among Americans with HPV16 viral infections

Study demonstrates in vitro infection and HEV replication in human hepatocytes

Entry inhibitors can provide first new hepatitis B & D treatments for many years

Experts must monitor new antiviral compounds for HCV treatment

Idera's IMO-2125 plus ribavirin Phase 1 trial results against HCV presented at EASL meeting

MSD's Victrelis Phase III trial final results against HCV presented at EASL meeting

Boehringer Ingelheim's BI 201335 new data against HCV highlighted at EASL meeting

Boehringer Ingelheim advances into Phase 3 clinical trial of BI 201335

Series of new clinical trials confirm range of viable treatment options for HCV patients

Oral Cancer Awareness Week aims to educate people regarding importance of early detection

Results of Boehringer Ingelheim's BI 201335 study presented at Annual Meeting of EASL

Microbix closes private financing for $0.35 per share

Invida, Roche partner to commercialize primary care products

Lymphocyte-hepatocyte interactions: Hepatitis C virus changes the rules

Potential HIV vaccine component undergoes dramatic protein rearrangement

Scientists engineer new protein that prevents HIV virus entry into cells

New research finds HIV virus's V3 loop as attractive vaccine target

Microplate-based assays in virology research eBook eBook

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging